BGMS Bio Green Med Solution, Inc. - Common Stock
$0.91
मूल्य · अग 18, 2026
मौलिकता इस प्रकार है अग 14, 2026
52W रेंज
$1–$9
4% of range
विश्लेषक रेटिंग
HOLD
6 analysts
मूल्य लक्ष्य
—
P/E (TTM)
-0.1
ROE
-57.2%
शुद्ध लाभ मार्जिन
—
Bio Green Med Solution, Inc. - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
Cyclacel Pharmaceuticals Inc. is a biotechnology firm based in Dundee, Scotland, and Short Hills, New Jersey, developing cancer drugs and treatments. Cyclacel was founded in 1996 by David Lane, Merlin Ventures and Cancer Research Campaign Technology with the University of Dundee and the University of Glasgow.
और पढ़ें
Cyclacel Pharmaceuticals Inc. is a biotechnology firm based in Dundee, Scotland, and Short Hills, New Jersey, developing cancer drugs and treatments. Cyclacel was founded in 1996 by David Lane, Merlin Ventures and Cancer Research Campaign Technology with the University of Dundee and the University of Glasgow.
Company overview
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle.
Three product candidates are currently in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analogue, failed its Phase 3 trial for the treatment of acute myeloid leukemia (AML) in the elderly. Phase 1/2 studies are ongoing for the treatment of breast cancer and AML/MDS. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors.
Cyclacel Pharmaceuticals' ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia.
Reverse merger
After becoming the first European spin-out company to raise over $100 million in private equity, the company had to pull out of a stock market listing in July 2004. Cyclacel completed a reverse merger with Xcyte Therapies in December 2005 to acquire Nasdaq listing. This allowed Cyclacel to raise an additional $45 million in April 2006 through a private placement of stock and warrants.
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
BGMS स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
मूल्य
$0.91
मार्केट कैप
$5M
P/E (TTM)
-0.1
EPS (TTM)
$-6.45
राजस्व (TTM)
$0
लाभांश प्रतिफल
—
ROE
-57.2%
D/E ऋण/इक्विटी
—
52W रेंज
$1 – $9
BGMS स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
Configure
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
राजस्व और शुद्ध आय
$0
2021-12-31
→
2025-12-31
EPS
$-6.45
2021-12-31
→
2025-12-31
फ्री कैश फ्लो
—
2021-12-31
→
2022-12-31
मार्जिन
—
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
मेट्रिक
5Y रुझान
BGMS
सहकर्मी माध्यिका
P/E (TTM)
-0.1
—
P/B
0.7
—
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
मेट्रिक
5Y रुझान
BGMS
सहकर्मी माध्यिका
ROA
-48.8%
-106.7%
ROE
-57.2%
-51.9%
ROIC
-123.4%
—
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
मेट्रिक
5Y रुझान
BGMS
सहकर्मी माध्यिका
Current Ratio (वर्तमान अनुपात)
4.7
3.3
Quick Ratio (त्वरित अनुपात)
3.6
—
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
मेट्रिक
5Y रुझान
BGMS
सहकर्मी माध्यिका
Revenue YoY (राजस्व YoY)
-89.8%
—
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
मेट्रिक
5Y रुझान
BGMS
सहकर्मी माध्यिका
लाभांश यील्ड, भुगतान अनुपात, लाभांश इतिहास, 5Y CAGR
लाभांश यील्ड
—
भुगतान अनुपात
—
5Y लाभांश CAGR
—
| एक्स-डेट | राशि |
|---|---|
| 29 अप्रैल 2025 | $36.0000 |
BGMS विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
बेचें
6 विश्लेषक
- मजबूत खरीद 0 0.0%
- खरीदें 0 0.0%
- होल्ड 3 50.0%
- बेचें 1 16.7%
- मजबूत बिक्री 2 33.3%
Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
औसत आश्चर्य
208.9%
| Period | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|
| 30 सितमबर 2024 | $-43.20 | $-135.86 | 92.7% |
| 30 जून 2024 | $-172.80 | $-351.29 | 178.5% |
| 31 मार्च 2024 | $-544.80 | $-1161.58 | 616.8% |
| 31 दिसमबर 2023 | $-1495.20 | $-1442.69 | -52.5% |
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
| टिकर | मार्केट कैप | P/E | राजस्व YoY | शुद्ध मार्जिन | ROE | सकल मार्जिन |
|---|---|---|---|---|---|---|
| BGMS | $8M | -0.2 | -89.8% | — | -57.2% | — |
| ALPS | — | — | — | — | — | — |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण 15
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $43.0K | $420.0K | $0 | $0 | $0 | · | $150.0K | · | · | · | · | |
| R&D Expense | $848.0K | $7M | $19M | $20M | $15M | $5M | $5M | $4M | · | · | · | · | |
| SG&A Expense | $8M | $5M | $7M | $7M | $7M | $6M | $5M | $5M | · | · | · | · | |
| Operating Expenses | $9M | $12M | $26M | $28M | $22M | $11M | $10M | $10M | · | · | · | · | |
| Operating Income | $-8M | $-12M | $-25M | $-28M | $-22M | $-11M | $-10M | $-10M | · | · | · | · | |
| Interest Income | · | $12.0K | $266.0K | $210.0K | $16.0K | $42.0K | $224.0K | $331.0K | · | · | · | · | |
| Other Non-op | $354.0K | $52.0K | $50.0K | $1M | $204.0K | $955.0K | $556.0K | $923.0K | · | · | · | · | |
| Pretax Income | $-3M | $-12M | $-26M | $-26M | $-22M | $-10M | $-9M | $-9M | · | · | · | · | |
| Income Tax | $7.0K | $-782.0K | $-3M | $-5M | $-4M | $-1M | $-1M | $-1M | · | · | · | · | |
| Net Income | $-3M | $-11M | $-23M | $-21M | $-18M | $-8M | $-8M | $-7M | · | · | · | · | |
| EPS (Basic) | $-6.45 | $-502.46 | $-6419.18 | $-1.90 | $-2.09 | $-3.42 | · | · | · | · | · | · | |
| EPS (Diluted) | $-6.45 | $-502.46 | $-6419.18 | $-27.24 | $-2.09 | $-3.42 | · | · | · | · | · | · | |
| Shares (Basic) | 2,185,075 | 22,314 | 3,545,000 | 11,255,677 | 8,926,173 | 3,633,385 | · | · | · | · | · | · | |
| Shares (Diluted) | 2,185,075 | 22,314 | 3,545,000 | 11,255,677 | 8,926,173 | 3,633,385 | · | · | · | · | · | · | |
| EBITDA | $-8M | $-12M | · | $-28M | $-23M | $-11M | $-10M | · | · | · | · | · |
बैलेंस शीट 25
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4M | $3M | $3M | $18M | $37M | $33M | $12M | $18M | · | · | · | · | |
| Short-term Investments | · | · | · | $5M | $4M | $5M | $11M | $17M | · | · | · | · | |
| Receivables | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Inventory | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $110.0K | $537.0K | $4M | $6M | $4M | $2M | $2M | $2M | · | · | · | · | |
| Other Current Assets | · | $300.0K | $341.0K | $426.0K | $79.0K | $66.0K | $103.0K | $236.0K | · | · | · | · | |
| Current Assets | $6M | $4M | $7M | $24M | $41M | $35M | $14M | $20M | · | · | · | · | |
| PP&E (Net) | $137.0K | $3.0K | $9.0K | $32.0K | $64.0K | $106.0K | $27.0K | $36.0K | · | · | · | · | |
| PP&E (Gross) | $421.0K | $427.0K | $429.0K | $415.0K | $425.0K | $991.0K | $6M | $6M | · | · | · | · | |
| Accum. Depreciation | $284.0K | $424.0K | $420.0K | $383.0K | $361.0K | $886.0K | $6M | $6M | · | · | · | · | |
| Goodwill | $2M | · | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $8M | $4M | $9M | $28M | $43M | $37M | $15M | $20M | · | · | · | · | |
| Accounts Payable | $617.0K | $5M | $4M | $3M | $2M | $514.0K | $890.0K | $3M | · | · | · | · | |
| Accrued Liabilities | $715.0K | $2M | $5M | $5M | $3M | $2M | $2M | $2M | · | · | · | · | |
| Current Liabilities | $1M | $6M | $8M | $8M | $5M | $2M | $2M | $4M | · | · | · | · | |
| Capital Leases | $2.0K | · | $37.0K | $106.0K | $30.0K | $1M | $1M | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $100.0K | · | · | · | · | |
| Total Liabilities | $1M | $6M | $8M | $8M | $5M | $4M | $4M | $5M | · | · | · | · | |
| Common Stock | $5.0K | · | · | $1.0K | $10.0K | $6.0K | $1.0K | $12.0K | · | · | · | · | |
| Paid-in Capital | $461M | $438M | $430M | $423M | $423M | $400M | $370M | $366M | · | · | · | · | |
| Retained Earnings | $-454M | $-439M | $-428M | $-406M | $-385M | $-366M | $-358M | $-350M | · | · | · | · | |
| AOCI | $-39.0K | $-891.0K | $-908.0K | $-1M | $-748.0K | $-746.0K | $-819.0K | $-760.0K | · | · | · | · | |
| Stockholders' Equity | $7M | $-2M | $607.0K | $16M | $38M | $33M | $12M | $15M | $22M | · | · | · | |
| Liabilities + Equity | $8M | $4M | $9M | $28M | $43M | $37M | $15M | $20M | · | · | · | · | |
| Shares Outstanding | 5,400,320 | 36,913 | 4,412 | 628,139 | 9,993,135 | 6,246,896 | 859,998 | 12,497,447 | · | · | · | · |
नकदी प्रवाह 12
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | $20.0K | $20.0K | $29.0K | · | · | · | · | |
| Stock-based Comp | $2M | $592.0K | $1M | $2M | $1M | $430.0K | $466.0K | $331.0K | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $61.0K | $-2M | · | · | · | · | · | |
| Operating Cash Flow | $-5M | $-8M | $-16M | $-21M | $-19M | $-8M | $-9M | $-7M | · | · | · | · | |
| CapEx | · | · | $6.0K | $7.0K | $27.0K | $96.0K | $10.0K | $39.0K | · | · | · | · | |
| Investing Cash Flow | · | · | $-6.0K | $-7.0K | $-27.0K | $-96.0K | $28.0K | $-39.0K | · | · | · | · | |
| Stock Issued | · | · | · | · | $4M | $30M | $4M | $630.0K | · | · | · | · | |
| Net Stock Activity | · | · | · | · | $4M | $30M | $4M | · | · | · | · | · | |
| Financing Cash Flow | $5M | $8M | $848.0K | $3M | $22M | $30M | $4M | $429.0K | · | · | · | · | |
| Net Change in Cash | $368.0K | $-241.0K | $-15M | $-18M | $3M | $22M | $-6M | $-6M | · | · | · | · | |
| Taxes Paid | $18.0K | $2.0K | $2.0K | $2.0K | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | $-21M | $-19M | $-8M | $-9M | · | · | · | · | · |
लाभप्रदता 7
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -27916.3% | · | · | · | · | · | · | · | · | · | · | |
| Net Margin | · | -26074.4% | · | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | · | -27893.0% | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | · | -27916.3% | · | · | · | · | · | · | · | · | · | · | |
| ROA | -48.8% | -173.8% | · | · | -43.0% | -32.4% | -44.6% | · | · | · | · | · | |
| ROE | -57.2% | 713.2% | · | · | -47.9% | -29.3% | -61.3% | · | · | · | · | · | |
| ROIC | -123.4% | 516.2% | · | · | -51.1% | -27.9% | -71.0% | · | · | · | · | · |
तरलता और शोधन क्षमता 2
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.7 | 0.6 | · | · | 7.7 | 14.3 | 5.8 | · | · | · | · | · | |
| Quick Ratio | 3.6 | 0.5 | · | · | 7.8 | 15.6 | 9.5 | · | · | · | · | · |
दक्षता 2
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | · | 0.0 | · | · | · | · | · | · | · | |
| Receivables Turnover | 0.0 | · | · | · | · | · | · | · | · | · | · | · |
विकास दरें 1
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | -89.8% | · | · | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM) 10
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $43.0K | $420.0K | $0 | $0 | $0 | $823.0K | $150.0K | $823.0K | $823.0K | $823.0K | $823.0K | |
| Net Income TTM | $-3M | $-11M | $-23M | $-21M | $-18M | $-8M | $-8M | $-7M | $-8M | $-8M | $-8M | $-8M | |
| Market Cap | $8M | $3M | · | · | $139.94B | $175.64B | $829.73B | · | · | · | · | · | |
| P/E | -0.2 | -0.2 | -0.1 | -88.5 | -6700.5 | -8221.1 | · | · | · | · | · | · | |
| P/S | · | 78.3 | · | · | · | · | 1008173.4 | · | · | · | · | · | |
| P/B | 1.2 | -1.5 | · | · | 3755.6 | 5280.9 | 70935.0 | · | · | · | · | · | |
| P / Tangible Book | 1.5 | · | 1117.9 | 1897.5 | 3712.7 | 5280.9 | · | · | · | · | · | · | |
| P / Cash Flow | -1.7 | -0.4 | · | · | -7548.2 | -22137.3 | -87829.7 | · | · | · | · | · | |
| P / FCF | · | · | · | · | -7537.2 | -21872.7 | -87736.8 | · | · | · | · | · | |
| Earnings Yield | -435.8% | -550.9% | -1001.7% | -1.1% | -0.01% | -0.01% | · | · | · | · | · | · |
आय विवरण 15
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $357.0K | $743.0K | $-81.0K | $81.0K | · | · | $0 | $10.0K | $4.0K | $29.0K | $31.0K | $16.0K | $373.0K | $0 | $0 | $0 | |
| R&D Expense | · | · | $-47.0K | $5.0K | $68.0K | $822.0K | $880.0K | $950.0K | $2M | $3M | $4M | $5M | $5M | $6M | $7M | $4M | |
| SG&A Expense | $497.0K | $389.0K | $1M | $1M | $1M | $4M | $948.0K | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Operating Expenses | $754.0K | $1M | $2M | $1M | $1M | $4M | $2M | $2M | $4M | $4M | $5M | $7M | $6M | $7M | $9M | $6M | |
| Operating Income | $-418.0K | $-246.0K | $-1M | $-992.0K | $-1M | $-4M | $-2M | $-2M | $-4M | $-4M | $-5M | $-7M | $-6M | $-7M | $-9M | $-6M | |
| Interest Income | · | · | · | · | · | · | · | · | · | $2.0K | $23.0K | $50.0K | $77.0K | $116.0K | $122.0K | $67.0K | |
| Other Non-op | $31.0K | $31.0K | $333.0K | $9.0K | $2.0K | $10.0K | $0 | · | · | $52.0K | $-1.0K | $-9.0K | $-106.0K | $166.0K | $-255.0K | $14.0K | |
| Pretax Income | $-396.0K | $-167.0K | $-606.0K | $-988.0K | $-1M | $-4M | $-2M | $-2M | $-4M | $-4M | $-6M | $-7M | $-6M | $-7M | $-9M | $-6M | |
| Income Tax | $9.0K | $30.0K | $5.0K | · | $2.0K | · | $1M | $-210.0K | $-412.0K | $-1M | $-422.0K | $-668.0K | $-586.0K | $-1M | $-2M | $-1M | |
| Net Income | $-405.0K | $-197.0K | $-611.0K | $-988.0K | $-1M | $-81.0K | $-3M | $-2M | $-3M | $-3M | $-5M | $-6M | $-5M | $-6M | $-7M | $-5M | |
| EPS (Basic) | · | · | $-4.16 | $-1.31 | $-0.98 | $0.00 | $-284.21 | $-43.80 | $-172.18 | $-2.27 | · | · | $-0.44 | $-0.47 | · | $-0.42 | |
| EPS (Diluted) | · | · | $-4.16 | $-1.31 | $-0.98 | $0.00 | $-284.21 | $-43.80 | $-172.18 | $-2.27 | · | · | $-0.44 | $-7.00 | $-25.94 | $-0.42 | |
| Shares (Basic) | 5,598,701 | 5,458,564 | 816,121 | 1,912,495 | 1,360,626 | 365,231 | 5,668 | 44,681 | · | · | · | · | 12,551,794 | 12,539,189 | · | 12,314,679 | |
| Shares (Diluted) | 5,598,701 | 5,458,564 | 816,121 | 1,912,495 | 1,360,626 | 365,231 | 5,668 | 44,681 | · | · | · | · | 12,551,794 | 12,539,189 | · | 12,314,679 | |
| EBITDA | $-418.0K | $-246.0K | · | $-992.0K | $-1M | $-5M | · | $-2M | $-4M | $-4M | · | $-7M | $-6M | $-7M | · | $-6M |
बैलेंस शीट 23
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4M | $3M | $4M | $4M | $4M | $3M | $3M | $3M | $6M | $3M | $3M | $6M | $10M | $11M | $18M | $24M | |
| Receivables | $1M | $1M | $1M | $725.0K | · | · | · | · | · | · | · | · | · | · | · | · | |
| Inventory | $972.0K | $947.0K | $1M | $1M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $133.0K | $148.0K | $110.0K | $513.0K | $108.0K | $264.0K | $537.0K | $2M | $2M | $2M | $4M | $5M | $5M | $8M | $6M | $4M | |
| Other Current Assets | · | · | · | $460.0K | $58.0K | $194.0K | · | $309.0K | $300.0K | $365.0K | $341.0K | $2M | $2M | $595.0K | $426.0K | $170.0K | |
| Current Assets | $6M | $6M | $6M | $6M | $4M | $4M | $4M | $5M | $8M | $5M | $7M | $11M | $15M | $19M | $24M | $28M | |
| PP&E (Net) | $136.0K | $138.0K | $137.0K | $129.0K | $1.0K | $1.0K | $3.0K | $4.0K | $5.0K | $7.0K | $9.0K | $16.0K | $24.0K | $31.0K | $32.0K | $37.0K | |
| PP&E (Gross) | · | · | $421.0K | · | · | · | $427.0K | · | · | · | $429.0K | · | · | · | $415.0K | · | |
| Accum. Depreciation | · | · | $284.0K | · | · | · | $424.0K | · | · | · | $420.0K | · | · | · | $383.0K | · | |
| Goodwill | $2M | $2M | $2M | $2M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $8M | $8M | $8M | $8M | $4M | $4M | $4M | $5M | $8M | $6M | $9M | $12M | $16M | $22M | $28M | $31M | |
| Accounts Payable | $189.0K | $256.0K | $617.0K | $468.0K | $221.0K | $114.0K | $5M | $4M | $5M | $5M | $4M | $2M | $2M | $3M | $3M | $983.0K | |
| Accrued Liabilities | $503.0K | $540.0K | $715.0K | $534.0K | $539.0K | $549.0K | $2M | $2M | $2M | $3M | $5M | $7M | $5M | $5M | $5M | $3M | |
| Current Liabilities | $692.0K | $796.0K | $1M | $1M | $760.0K | $663.0K | $6M | $6M | $7M | $8M | $8M | $8M | $7M | $7M | $8M | $4M | |
| Capital Leases | · | · | $2.0K | $5.0K | $10.0K | $9.0K | · | $0 | $5.0K | $21.0K | $37.0K | $52.0K | $66.0K | $80.0K | $106.0K | $107.0K | |
| Total Liabilities | $694.0K | $804.0K | $1M | $1M | $770.0K | $672.0K | $6M | $6M | $7M | $8M | $8M | $8M | $7M | $7M | $8M | $4M | |
| Common Stock | $7.0K | $5.0K | $5.0K | $3.0K | $2.0K | $204.0K | · | $2.0K | $2.0K | $1.0K | · | $12.0K | $9.0K | $9.0K | $1.0K | $9.0K | |
| Paid-in Capital | $462M | $461M | $461M | $451M | $445M | $443M | $438M | $437M | $436M | $430M | $430M | $428M | $424M | $423M | $423M | $423M | |
| Retained Earnings | $-455M | $-455M | $-454M | $-444M | $-442M | $-440M | $-439M | $-436M | $-434M | $-431M | $-428M | $-423M | $-417M | $-412M | $-406M | $-399M | |
| AOCI | · | $-30.0K | $-39.0K | · | · | · | $-891.0K | $-1M | $-915.0K | $-898.0K | $-908.0K | $-1M | $-1M | $-1M | $-1M | $-2M | |
| Stockholders' Equity | $7M | $7M | $7M | $7M | $4M | $3M | $-2M | $-970.0K | $999.0K | $-2M | $607.0K | $4M | $5M | $10M | $16M | $22M | |
| Liabilities + Equity | $8M | $8M | $8M | $8M | $4M | $4M | $4M | $5M | $8M | $6M | $9M | $12M | $16M | $22M | $28M | $31M | |
| Shares Outstanding | 6,622,794 | 5,519,456 | 5,400,320 | 3,497,537 | 1,583,965 | 207,336,389 | 36,913 | 2,152,202 | 1,805,204 | 1,318,259 | 4,412 | 12,642,822 | 12,642,822 | 12,539,189 | 628,139 | 12,539,189 |
नकदी प्रवाह 8
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $0 | $1.0K | $655.0K | $6.0K | $7.0K | $2M | $93.0K | $107.0K | $189.0K | $203.0K | $322.0K | $391.0K | $359.0K | $401.0K | $387.0K | $389.0K | |
| Operating Cash Flow | $-352.0K | $-278.0K | $-33.0K | $-434.0K | $-1M | $-3M | $-1M | $-3M | $-3M | $-483.0K | $-4M | $-4M | $-1M | $-7M | $-5M | $-7M | |
| CapEx | $0 | $1.0K | · | · | · | · | · | $0 | · | · | $0 | $0 | $0 | $6.0K | $0 | $0 | |
| Investing Cash Flow | $0 | $-1.0K | · | · | · | · | · | $0 | · | · | $0 | $0 | $0 | $-6.0K | $0 | $0 | |
| Financing Cash Flow | $773.0K | $105.0K | $-259.0K | $-3.0K | $2M | $4M | $2M | $-1.0K | $6M | $-79.0K | $999.0K | $-50.0K | $-51.0K | $-50.0K | $42.0K | $2M | |
| Net Change in Cash | $451.0K | $-166.0K | $-333.0K | $-437.0K | $825.0K | $313.0K | $155.0K | $-3M | $3M | $-580.0K | $-3M | $-4M | $-1M | $-7M | $-5M | $-5M | |
| Taxes Paid | · | · | · | · | · | · | $0 | $0 | $0 | $2.0K | $0 | $0 | $0 | $2.0K | $0 | $0 | |
| Free Cash Flow | · | $-279.0K | · | · | · | · | · | · | · | · | · | · | · | $-7M | · | · |
लाभप्रदता 7
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -4644.4% | -33.1% | · | -1224.7% | -65850.0% | -83933.3% | · | -21770.0% | -91100.0% | -15017.2% | · | -42781.2% | -1589.5% | · | · | · | |
| Net Margin | -4500.0% | -26.5% | · | -1219.8% | -65900.0% | -1350.0% | · | -19570.0% | -81425.0% | -10158.6% | · | -37700.0% | -1460.6% | · | · | · | |
| Pretax Margin | -4400.0% | -22.5% | · | -1219.8% | -65800.0% | -1350.0% | · | -21670.0% | -91725.0% | -14827.6% | · | -41875.0% | -1617.7% | · | · | · | |
| EBITDA Margin | -4644.4% | -33.1% | · | -1224.7% | -65850.0% | -83933.3% | · | -21770.0% | -91100.0% | -15017.2% | · | -42781.2% | -1589.5% | · | · | · | |
| ROA | -6.6% | -3.5% | · | -14.6% | -20.9% | -1.6% | · | -21.9% | -26.5% | -20.9% | · | -27.7% | -21.0% | -18.8% | · | -13.4% | |
| ROE | -7.5% | -4.0% | · | -32.3% | -56.9% | -18.9% | · | -117.6% | -106.2% | -74.2% | · | -45.8% | -30.8% | -26.7% | · | -16.1% | |
| ROIC | -6.0% | -4.3% | · | · | -36.3% | · | · | 202.7% | -323.8% | 135.2% | · | -143.4% | -104.2% | -58.8% | · | -24.4% |
तरलता और शोधन क्षमता 2
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.6 | 7.1 | · | 6.4 | 5.8 | 5.6 | · | 0.8 | 1.1 | 0.6 | · | 1.4 | 2.3 | 2.6 | · | 6.4 | |
| Quick Ratio | 7.0 | 5.7 | · | 4.6 | 5.6 | 5.2 | · | 0.5 | 0.8 | 0.3 | · | 0.7 | 1.5 | 1.6 | · | 5.4 |
दक्षता 2
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 0.0 | 1.3 | · | 0.2 | · | · | · | · | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM) 10
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | $59.0K | $59.0K | · | $59.0K | $422.0K | $418.0K | · | $389.0K | $373.0K | $0 | · | $0 | |
| Net Income TTM | $-3M | $-3M | · | $-4M | $-7M | $-8M | · | $-14M | $-18M | $-20M | · | $-22M | $-21M | $-20M | · | $-19M | |
| Market Cap | $6M | $6M | · | $17M | $8M | $13.93B | · | $511M | $702M | $668M | · | $15.93B | $26.85B | $25.73B | · | $65.91B | |
| P/E | -0.0 | -0.0 | · | -0.1 | -0.0 | -0.3 | · | · | · | · | · | -151.4 | -255.3 | -247.2 | · | -2903.9 | |
| P/S | · | · | · | · | 132.9 | 236152.6 | · | 8667.2 | 1663.2 | 1597.0 | · | 40951.0 | 71992.9 | · | · | · | |
| P/B | 0.8 | 0.8 | · | 2.4 | 2.2 | 4550.3 | · | -527.2 | 702.6 | -302.6 | · | 3707.2 | 5228.5 | 2535.5 | · | 2986.6 | |
| P / Tangible Book | 1.1 | 1.1 | · | 3.1 | 2.2 | 4550.3 | · | · | 702.6 | · | · | 3707.2 | 5228.5 | 2535.5 | · | 2986.6 | |
| P / Cash Flow | · | -19.9 | · | · | · | -4291.0 | · | · | · | -1382.1 | · | · | · | -3750.2 | · | · | |
| P / FCF | · | -19.8 | · | · | · | · | · | · | · | · | · | · | · | -3747.0 | · | · | |
| Earnings Yield | -5064.8% | -4609.0% | · | -933.0% | -4383.0% | -324.8% | · | · | · | · | · | -0.66% | -0.39% | -0.40% | · | -0.03% |
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
आय विवरण
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 | 2023-03-31 | |
|---|---|---|---|---|---|
| राजस्व | $0 | $43.0K | $420.0K | — | — |
| परिचालन मार्जिन % | — | -27916.3% | — | — | — |
| शुद्ध आय | $-3M | $-11M | $-23M | — | — |
| तनुकरणित EPS | $-6.45 | $-502.46 | $-6419.18 | — | — |
बैलेंस शीट
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 | 2023-03-31 | |
|---|---|---|---|---|---|
| वर्तमान अनुपात | 4.7 | 0.6 | — | — | — |
| त्वरित अनुपात | 3.6 | 0.5 | — | — | — |
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
📊
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
संस्थागत मालिक (13F) 7 फाइलर्स · $89K कुल · तिथि अनुसार 30 जून 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
संस्थागत गतिविधि — Q2 2026 बनाम पिछली तिमाही
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 1 (-2 पिछली तिमाही की तुलना में) | 3 (+1 पिछली तिमाही की तुलना में) | 4 (0 पिछली तिमाही की तुलना में) | 0 (0 पिछली तिमाही की तुलना में) | -21K |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | $68468 | 75240 | 76.95% | शेयर |
| JANE STREET GROUP, LLC | $10725 | 11786 | 12.05% | शेयर |
| Tower Research Capital LLC (TRC) | $5207 | 5722 | 5.85% | शेयर |
| UBS Group AG | $3942 | 4332 | 4.43% | शेयर |
| SBI Securities Co., Ltd. | $638 | 701 | 0.72% | शेयर |
| Archer Investment Corp | $1 | 1 | 0.00% | शेयर |
| OSAIC HOLDINGS, INC. | $0 | 1 | 0.00% | शेयर |
कंपनी के अंदरूनी सूत्र 55 इनसाइडर्स · 18 अधिकारी · 24 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Spiro George Rombotis | President and CEO | 21 दिसमबर 2023 P | 68658 | 0 | 0 | $0 |
| Ronald J Berenson | President and CEO | 3 फ़रवरी 2005 A | 430939 | 0 | 0 | $0 |
| Paul Mcbarron | E. VP, Fin, CFO, COO and Secretary | 21 दिसमबर 2023 P | 33378 | 0 | 0 | $0 |
| Stewart Craig | COO and VP | 3 फ़रवरी 2005 A | — | 0 | 0 | $0 |
| Brian Schwartz | Interim Chief Medical Officer | 29 जनवरी 2024 A | 15205 | 0 | 0 | $0 |
| Mark Kirschbaum | Chief Medical Officer | 30 जून 2023 A | 31200 | 0 | 0 | $0 |
| Judy Chiao | V.P., Clin. Dev. & Reg. Aff. | 5 दिसमबर 2019 A | 39024 | 0 | 0 | $0 |
| Robert Edward Sosnowski | VP, Marketing & Sales | 6 दिसमबर 2011 A | 28000 | 0 | 0 | $0 |
| William Collins | General Manager | 4 अप्रैल 2008 A | — | 0 | 0 | $0 |
| Gregory Reyes | Senior VP, Research | 22 दिसमबर 2007 A | 3000 | 0 | 0 | $0 |
| Robert Westwood | V.P., Chem. & Preclin. Dev. | 21 दिसमबर 2006 A | — | 0 | 0 | $0 |
| Robert Jackson | S.V.P. & Chief Scientific Offi | 14 जून 2006 A | 64841 | 0 | 0 | $0 |
| Lawrence A Romel | VP Clinical Operations | 3 फ़रवरी 2005 A | — | 0 | 0 | $0 |
| Mark Frohlich | Medical Director and VP | 3 फ़रवरी 2005 A | — | 0 | 0 | $0 |
| Joanna S Black | VP and General Counsel, Secret | 3 फ़रवरी 2005 A | — | 0 | 0 | $0 |
| Kathi L Cordova | SVP Finance, Treasurer | 3 फ़रवरी 2005 A | — | 0 | 0 | $0 |
| Mark L Bonyhadi | Vice President, Research | 3 फ़रवरी 2005 A | — | 0 | 0 | $0 |
| Robert L Kirkman | Chief Business Officer and VP | 3 फ़रवरी 2005 A | — | 0 | 0 | $0 |
| Avraham Ben-Tzvi | निदेशक | 26 फ़रवरी 2025 A | — | 0 | 0 | $0 |
| David Natan | निदेशक | 26 फ़रवरी 2025 A | 100000 | 0 | 0 | $0 |
| Kenneth M. Ferguson | निदेशक | 30 जून 2023 A | 44952 | 0 | 0 | $0 |
| Karin L Walker | निदेशक | 30 जून 2023 A | 40602 | 0 | 0 | $0 |
| Robert J. Spiegel | निदेशक | 30 जून 2023 A | 39415 | 0 | 0 | $0 |
| Christopher S Henney | निदेशक | 30 जून 2023 A | 39415 | 0 | 0 | $0 |
| Sam L Barker | निदेशक | 30 जून 2023 A | 40415 | 0 | 0 | $0 |
| Lloyd Sems | निदेशक | 14 जून 2022 A | 18196 | 0 | 0 | $0 |
| Gregory T. Hradsky | निदेशक | 15 जून 2021 A | 2374 | 0 | 0 | $0 |
| John Michael Middlecott Banham | निदेशक | 25 जून 2020 A | 36847 | 0 | 0 | $0 |
| David C Uprichard | निदेशक | 25 जून 2020 A | 25306 | 0 | 0 | $0 |
| Nicholas G Bacopoulos | निदेशक | 22 मई 2013 A | — | 0 | 0 | $0 |
| Daniel K Spiegelman | निदेशक | 23 मई 2012 A | — | 0 | 0 | $0 |
| Pierre Legault | निदेशक | 19 फ़रवरी 2008 A | — | 0 | 0 | $0 |
| John Gordon Mcvie | निदेशक | 19 फ़रवरी 2008 A | — | 0 | 0 | $0 |
| Peter Langecker | निदेशक | 17 जून 2005 A | 5000 | 0 | 0 | $0 |
| Robert Michael Williams | निदेशक | 17 जून 2005 A | 45700 | 0 | 0 | $0 |
| Robert Nelsen | निदेशक | 17 जून 2005 A | 2054271 | 0 | 0 | $0 |
| Stephen Wertheimer | निदेशक | 17 जून 2005 A | 574363 | 0 | 0 | $0 |
| Robert E Curry | निदेशक | 19 मार्च 2004 X | 960964 | 0 | 0 | $0 |
| Lazar David E. | 10% मालिक | 30 जुलाई 2025 S | 155838 | 0 | 0 | $0 |
| MARXE AUSTIN W & GREENHOUSE DAVID M | 10% मालिक | 23 सितमबर 2011 S | 2806900 | 0 | 0 | $0 |
| MORGAN STANLEY | 10% मालिक | 10 नवमबर 2009 S | 2276852 | 0 | 0 | $0 |
| HEALTHCARE FOCUS FUND LP | 10% मालिक | 29 अक्टूबर 2004 P | 1684870 | 0 | 0 | $0 |
| Clinton Bybee | 10% मालिक | 29 अक्टूबर 2004 P | 2054271 | 0 | 0 | $0 |
| Keith Crandell | 10% मालिक | 29 अक्टूबर 2004 P | 2054271 | 0 | 0 | $0 |
| ARCH V ENTREPRENEURS FUND LP | 10% मालिक | 29 अक्टूबर 2004 P | 2052847 | 0 | 0 | $0 |
| ARCH VENTURE FUND V LP | 10% मालिक | 29 अक्टूबर 2004 P | 1704763 | 0 | 0 | $0 |
| Steven Lazarus | 10% मालिक | 29 अक्टूबर 2004 P | 2054271 | 0 | 0 | $0 |
| ARCH VENTURE FUND III L P | 10% मालिक | 29 अक्टूबर 2004 P | 913784 | 0 | 0 | $0 |
| ARCH VENTURE FUND II LP | 10% मालिक | 29 अक्टूबर 2004 P | 1860824 | 0 | 0 | $0 |
| CREDIT SUISSE/ | 10% मालिक | 19 मार्च 2004 X | 960964 | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
कार्यकर्ता और 5%+ मालिक 7 होल्डिंग्स
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| Doris Wong Sing Ee ×2 फाइलिंग | 13 नवमबर 2025 | 20.58% | संशोधन | — | SEC |
| Lazar David E. ×3 फाइलिंग | 8 अगस्त 2025 | 0.00% | संशोधन | — | SEC |
| Tang Capital Partners, LP, Tang Capital Management, LLC, Kevin C. Tang ×3 फाइलिंग | 22 नवमबर 2017 | — | प्रारंभिक फाइलिंग | — | SEC |
| EASTERN CAPITAL LIMITED, PORTFOLIO SERVICES LTD., KENNETH B. DART | 27 जुलाई 2017 | — | प्रारंभिक फाइलिंग | — | SEC |
| Austin W. Marxe and David M. Greenhouse ×3 फाइलिंग | 3 अगस्त 2009 | — | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
| 13 अप्रैल 2006 | — | प्रारंभिक फाइलिंग | — | SEC | |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 12 नवमबर 2004 | — | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.